Home › Research › Health systems and care delivery
Cost of Psychiatric Inpatient Treatment for Dementia in Switzerland: A Case-Level Analysis of Billing Data
Bleibtreu Elena, Riese Florian. International journal of geriatric psychiatry, 2025-07-05
Topic: Risk, prevention and care in population studies
Plain-language summary
The objective of this study was to investigate the cost of care for patients with a primary diagnosis of dementia in Swiss hospitals under the new TARPSY reimbursement system. We used a dataset of the Swiss hospital reimbursement system TARPSY from 2016 to 2019, including all relevant remuneration variables at the patient level, to investigate hospital costs. Costs were analyzed by geographic location and hospital type. Homogeneity coefficients were used to analyze case cost homogeneity. We identified 7090 cases in the TARPSY database who were treated in Swiss hospitals under the primary diagnosis of dementia from 2016 to 2019. Of these, 6747 cases were included in our analysis. The total case costs and daily costs increased from 2016 to 2019, whereas the length of stay decreased. The average total case cost in 2019 was CHF 34,917 (σ = 32,926), corresponding to a daily cost of CHF 946 (σ = 373.44). Patients were treated for an average of 39.7 (σ = 32.40) days. In 2019, the total costs billed according to TARPSY for 57,939 days of hospital care for dementia as the primary diagnosis were CHF 51.3 million. The case costs differed by region and hospital type. Overall, cost homogeneity for total case cost as a proxy for the quality of the cost calculation was "satisfactory, sufficient" and did not show a clear trend towards improvement during the introduction of TARPSY. Our analysis provides reliable, case-level cost data for dementia hospital treatment in Switzerland. The total cost of dementia treatment in psychiatric hospitals appears to be much lower than previous estimates had indicated. When correcting for changes in accounting practices, total case costs only increased modestly from 2016 to 2019.
What this study adds
Evidence grade: Low
This study analyzed the cost of psychiatric inpatient treatment for dementia in Swiss hospitals under the TARPSY reimbursement system, finding rising case and daily costs with decreasing length of stay. It is a cost analysis and provides no information on treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Elena, B., & Florian, R. (2025). Cost of Psychiatric Inpatient Treatment for Dementia in Switzerland: A Case-Level Analysis of Billing Data. International journal of geriatric psychiatry. https://doi.org/10.1002/gps.70122
Vancouver
Elena B, Florian R. Cost of Psychiatric Inpatient Treatment for Dementia in Switzerland: A Case-Level Analysis of Billing Data. International journal of geriatric psychiatry. 2025. doi:10.1002/gps.70122. PMID: 40616254.
BibTeX
@article{elena2025-40616254,
author = {Elena, Bleibtreu and Florian, Riese},
title = {{Cost of Psychiatric Inpatient Treatment for Dementia in Switzerland: A Case-Level Analysis of Billing Data}},
journal = {International journal of geriatric psychiatry},
year = {2025},
doi = {10.1002/gps.70122},
pmid = {40616254},
url = {https://doi.org/10.1002/gps.70122}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Overall, cost homogeneity for total case cost as a proxy for the quality of the cost calculation was "satisfactory, sufficient" and did not show a clear trend towards improvement during the introduction of TARPSY.
Why it matters
This study analyzed the cost of psychiatric inpatient treatment for dementia in Swiss hospitals under the TARPSY reimbursement system, finding rising case and daily costs with decreasing length of stay. It is a cost analysis and provides no information on treating, curing, or preventing Alzheimer's disease.
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here and still being cited, so those were left out: it earned 29 of the 72 points we could judge it on, which is 40 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International journal of geriatric psychiatry) |
| Journal's citation record | 2 / 4 | International Journal of Geriatric Psychiatry: journal h-index 190 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | Citation count not trusted: 2 of 7 library studies citing it were published more than a year before it - a sign OpenAlex merged several works under this DOI — left out of this score |
| Citations per year | — / 5 | Citation count not trusted (see above) — left out of this score |
| Impact for its field and year | — / 6 | Citation count not trusted (see above) — left out of this score |
| Cited by studies here | — / 6 | Library citations not trusted (see above) — left out of this score |
| Still being cited | — / 4 | Citation count not trusted (see above) — left out of this score |
| Senior author's track record | 2 / 4 | Last-listed author Florian Riese: h-index 21 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Zurich: institution h-index 1,216 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40616254) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 29 / 72 | Scored on 15 of 20 parts. We have no data for the rest, so they are left out: 29 of the 72 points we could judge it on is 40 out of 100. |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Health systems and care delivery from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.